Literature DB >> 17560012

Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.

Chris Sjostrom1, Charles Seiler, David K Crockett, Sheryl R Tripp, Kojo S J Elenitoba Johnson, Megan S Lim.   

Abstract

OBJECTIVE: Constitutive overexpression of nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) is a key oncogenic event in anaplastic large cell lymphomas (ALCL) that carry the t(2;5)(p23;q35) translocation. Global proteomic analysis of NPM/ALK-positive ALCL would improve understanding of the disease pathogenesis and yield new candidate targets for novel treatment and diagnostic strategies.
MATERIALS AND METHODS: To comprehensively determine the inventory of proteins from NPM/ALK-positive ALCL SUDHL-1 cells, the membrane, cytoplasm, and nuclear subcellular fractions were resolved by one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MS spectra were interpreted using SEQUEST to search the electronic UniProt protein database, and analyzed by ProteinProphet and INTERACT.
RESULTS: A total of 623 proteins consisting of 210 membrane, 229 cytoplasm, and 184 nuclear proteins were identified with a <or=5% error rate. Extensive annotation and systematic examination of the literature for information on 209 representative proteins indicated that 19.9% were reported to be expressed in T cells and 44.7% were reported to have important function in cancers, while only 4.3% were reported to be involved in ALCL pathogenesis. Categorization of proteins into functional groups was performed using GOMiner. A subset of the identified proteins was confirmed by Western blots and immunohistochemistry of tissue samples.
CONCLUSION: We present an extensive catalog of proteins expressed by NPM/ALK-positive ALCL. This study illustrates the potential for novel pathogenetic discovery in NPM/ALK-positive ALCL and the utility of combining cellular subfractionation, 1D SDS-PAGE, and LC-MS/MS for the comprehensive protein analysis of lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560012     DOI: 10.1016/j.exphem.2007.04.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.

Authors:  Serina Ortiz; Wenhui Lee; David Smith; Stephen J Forman; Terry D Lee; Chih-Pin Liu
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

Review 2.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

3.  The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

Authors:  Francesco E Boccalatte; Claudia Voena; Chiara Riganti; Amalia Bosia; Lucia D'Amico; Ludovica Riera; Mangeng Cheng; Bruce Ruggeri; Ole N Jensen; Valerie L Goss; Kimberly Lee; Julie Nardone; John Rush; Roberto D Polakiewicz; Michael J Comb; Roberto Chiarle; Giorgio Inghirami
Journal:  Blood       Date:  2008-10-09       Impact factor: 22.113

Review 4.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

5.  ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.

Authors:  Fabrizio Tabbó; Antonella Barreca; Roberto Piva; Giorgio Inghirami
Journal:  Front Oncol       Date:  2012-05-11       Impact factor: 6.244

Review 6.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

7.  Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.

Authors:  Katerina Kourentzi; Mary Crum; Ujwal Patil; Ana Prebisch; Dimple Chavan; Binh Vu; Zihua Zeng; Dmitri Litvinov; Youli Zu; Richard C Willson
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.